← Back to Analyst Consensus 
GOSS Buy
Gossamer Bio, Inc.
Current Price —
Implied Upside —
Analysts 13
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Next Earnings
Nov 3, 2026 (8 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 15, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Oct 13, 2026 | Chardan Capital | initiate | — → Buy | — | 47% |
| Sep 21, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Aug 14, 2026 | Piper Sandler | maintain | Overweight → Overweight | — | 54% |
| Jul 28, 2026 | Leerink Partners | upgrade | Market Perform → Outperform | — | 50% |
| Jul 27, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jun 25, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| May 26, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| May 19, 2026 | Barclays | maintain | Underweight → Underweight | — | 53% |
| Mar 23, 2026 | Cantor Fitzgerald | downgrade | Overweight → Neutral | — | 50% |
| Mar 6, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 5, 2026 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| Feb 24, 2026 | Wedbush | downgrade | Outperform → Neutral | $1 | 58% |
| Feb 24, 2026 | Barclays | downgrade | Overweight → Underweight | $0.3 | 53% |
| Feb 24, 2026 | Leerink Partners | downgrade | Outperform → Market Perform | $1 | 50% |
| Jan 28, 2026 | Barclays | initiate | — → Overweight | $9 | 53% |
| Jan 22, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Sep 11, 2025 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $0 | 50% |
| Sep 10, 2025 | UBS | upgrade | Neutral → Buy | $9 | 54% |
| Aug 6, 2025 | Wedbush | maintain | Outperform → Outperform | $5 | 58% |
| Jul 14, 2025 | Scotiabank | initiate | — → Sector Outperform | $11 | 55% |
| May 16, 2025 | Goldman Sachs | maintain | Buy → Buy | $8 | 54% |
| May 16, 2025 | Wedbush | reiterate | Outperform → Outperform | $4 | 58% |
| Apr 17, 2025 | Goldman Sachs | maintain | Buy → Buy | $7 | 54% |
| Mar 14, 2025 | Wedbush | reiterate | Outperform → Outperform | $4 | 58% |
| Jan 30, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Nov 11, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Sep 17, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Aug 30, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Aug 13, 2024 | Wedbush | reiterate | Outperform → Outperform | $4 | 58% |
| Jun 25, 2024 | Oppenheimer | initiate | — → Outperform | $9 | 52% |
| Jun 17, 2024 | Goldman Sachs | maintain | Buy → Buy | $8 | 54% |
| May 20, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| May 8, 2024 | Wedbush | reiterate | Outperform → Outperform | $4 | 58% |
| May 6, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Mar 27, 2024 | Piper Sandler | maintain | Overweight → Overweight | $15 | 54% |
| Mar 6, 2024 | Goldman Sachs | maintain | Buy → Buy | $8 | 54% |
| Mar 6, 2024 | Wedbush | reiterate | Outperform → Outperform | $6 | 58% |
| Mar 6, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Jan 8, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $10 | 44% |
| Dec 19, 2023 | Wedbush | reiterate | Outperform → Outperform | $6 | 58% |
| Nov 10, 2023 | Wedbush | maintain | Outperform → Outperform | $6 | 58% |
| Aug 11, 2023 | Wedbush | reiterate | Outperform → Outperform | $5 | 58% |
| Aug 10, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $5 | 44% |
| Jul 26, 2023 | Wedbush | maintain | Outperform → Outperform | $5 | 58% |
| Jul 26, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $5 | 44% |
| Jul 21, 2023 | Wedbush | reiterate | Outperform → Outperform | $7 | 58% |
| May 11, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $5 | 44% |
| Mar 21, 2023 | Barclays | maintain | — → Equal-Weight | $1.5 | 53% |
| Mar 7, 2023 | Raymond James | downgrade | Outperform → Market Perform | $5 | 54% |
Price Target Trend
Jun 17, 2026 Oct 26, 2026
EPS Estimates
+1y —
0q —
+1q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days